AC-262

Description

AC-262

Buy AC-262 (Accadrine) Online

AC-262,536, commonly referred to as Accadrine or AC-262, is an experimental selective androgen receptor modulator (SARM). It was developed to investigate tissue-selective androgen receptor activity and has attracted attention for its anabolic properties in preclinical models.

Unlike approved androgen therapies, AC-262 has not established a clinical safety or efficacy profile in humans.

Product Information

AC-262 is a non-steroidal compound that acts as a partial agonist at the androgen receptor. Preclinical pharmacological characterization found anabolic activity in animal models with comparatively lower androgenic activity than testosterone.

How Does It Work?

AC-262 binds to androgen receptors and activates androgen-responsive signaling. Its tissue-selective profile was investigated to determine whether anabolic effects could be separated from unwanted androgenic effects.

Benefits

Anabolic Research Potential

Animal research demonstrated meaningful anabolic activity, particularly in skeletal muscle-related endpoints, which is the primary reason AC-262 remains of interest in performance-related research.

Selective Androgen-Receptor Activity

AC-262 was designed around the concept of selective androgen receptor modulation, attempting to produce anabolic signaling with less activity in androgen-sensitive tissues.

Muscle & Bone Research Interest

Because androgen receptors regulate muscle, bone, and other tissues, AC-262 provides a research model for studying selective androgen signaling.

Alternative SARM Research Candidate

AC-262 has become particularly interesting to researchers comparing different SARMs and their relative anabolic-to-androgenic profiles.

Side Effects

Human safety data are essentially absent. Potential risks therefore cannot be reliably quantified. Based on its pharmacology, concerns include testosterone suppression, changes in lipids, liver effects, androgenic effects, and unknown cardiovascular or reproductive consequences.

AC-262 is also prohibited in sport under WADA’s S1 anabolic-agent category.

Dosage

There is no established human dose for AC-262.

Online research/community sources commonly mention 10–30 mg/day, but these figures are speculative and are not supported by human clinical trials.

Animal experiments have used considerably different doses depending on study design, including ranges around 3–30 mg/kg in rats.

Where to Buy AC-262

Purerawz does not sell or directly supply AC-262. Where available, affiliate links may lead to independent third-party research suppliers.

References

1. Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator. Endocrinology.
PubMed — PMID: 18164613
2. AC-262,536 and anabolic-agent classification. WADA-related documentation.

Disclaimer

Purerawz does not sell, manufacture, stock, dispense, or directly supply any of the products discussed on this website. Purerawz is an independent information and affiliate platform. Where available, links may direct readers to independent third-party providers, and Purerawz may receive a commission from qualifying purchases at no additional cost to the reader.

The information is educational only.